Quantitative analysis for Adlai Nortye Ltd. (ANL) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Buy (65.0) (grade B). Gem alpha score: 41.0. 29 signals analyzed (23 differentiated alt-data).
ANL stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-30 | $15.00 | $12.85 | $14.27 |
| 2026-05-12 | $13.62 | $12.60 | $13.15 |
| 2026-05-22 | $12.07 | $11.53 | $11.92 |
| 2026-06-04 | $11.38 | $10.50 | $11.00 |
| 2026-06-16 | $10.92 | $10.02 | $10.05 |
| 2026-06-29 | $11.51 | $9.85 | $11.41 |
| 2026-07-10 | $10.60 | $9.63 | $9.87 |
| 2026-07-22 | $13.30 | $12.17 | $13.26 |
| 2026-08-03 | $13.41 | $12.70 | $12.99 |
| 2026-08-13 | $13.18 | $12.50 | $12.86 |
| 2026-08-25 | $14.29 | $13.55 | $13.74 |
| 2026-09-04 | $16.02 | $14.55 | $15.01 |
How Adlai Nortye Ltd. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| BWAY | BrainsWay Ltd. | $599M | — |
| CTMX | CytomX Therapeutics, Inc. | $598M | 50.0 |
| TLRY | Tilray Brands, Inc. | $647M | — |
| PROK | ProKidney Corp. | $545M | — |
View all Health Care stocks by valuation and signals →
Adlai Nortye Ltd. (ANL) scores Buy (65.0), and the composite conceals a 82-point disagreement between its dimensions. It is strongest on ML forecast at 88 and technicals at 73, and weakest on AI Alpha (gem) at 10 and analyst consensus at 6. A stock can carry ML forecast that high while analyst consensus sits at 6; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| ML forecast | 88 |
| technicals | 73 |
| valuation | 72 |
| AI Alpha (gem) | 10 |
| analyst consensus | 6 |
StoQuant analyzes 29 signals (23 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Adlai Nortye Ltd. (ANL): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/ANL"><img src="https://stoquant.com/badge/ANL.svg" alt="Adlai Nortye Ltd. (ANL) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.